DEA lets Maridose LLC apply to import marijuana extracts officially
Published Date: 3/26/2025
Notice
Summary
Maridose LLC wants to become an official importer of certain controlled substances like marijuana and its extracts. People and companies involved can share their thoughts or ask for a hearing by April 25, 2025. This move could impact businesses dealing with these substances and involves a formal review process with no immediate cost changes announced.
Analyzed Economic Effects
3 provisions identified: 1 benefits, 2 costs, 0 mixed.
Application to Import Schedule I Cannabis Materials
Maridose, LLC applied on January 27, 2025 to be registered to import three Schedule I drug classes: Marihuana Extract (code 7350), Marihuana (code 7360), and Tetrahydrocannabinols (code 7370). The company says it plans to import these substances for sale to research facilities for drug testing and analysis; the public may comment or request a hearing on the application on or before April 25, 2025.
Import Limited to Synthetic CBD and THC
For drug codes 7360 (Marihuana) and 7370 (Tetrahydrocannabinols), Maridose plans to import a synthetic cannabidiol and a synthetic tetrahydrocannabinol. The registration does not authorize any other activities for those two drug codes.
No Import of Finished Dosage Forms for Commercial Sale
The notice states that authorization will not extend to the import of Food and Drug Administration-approved or non-approved finished dosage forms for commercial sale. Maridose's planned registration is limited to the activities described and cannot be used to import finished commercial drug products.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-11526, Implementation of the Substance Use-Disorder Prevention That Promotes Opioid Recovery and Treatment for Patients and Communities Act of 2018: Dispensing and Administering Controlled Substances for Medication-Assisted Treatment
Starting July 9, 2026, new rules make it easier for doctors and pharmacies to provide medicine that helps people recover from opioid addiction. These changes affect healthcare providers by expanding who can give medication-assisted treatment and how pharmacies can deliver these medicines. The goal? Faster, safer access to treatment with clear rules that save time and support recovery.
2026-10128, Revision of Applications for Manufacturing and Procurement Quotas
The DEA wants to update how companies apply for permission to make and buy certain controlled drugs and chemicals. These changes will make the rules clearer, help prevent drug shortages, and ensure enough supply for medical and scientific needs. If you’re a manufacturer or involved in this process, get ready to follow new steps and share your thoughts by July 20, 2026.
2025-05007, Expansion of Buprenorphine Treatment via Telemedicine Encounter and Continuity of Care via Telemedicine for Veterans Affairs Patients
Starting December 31, 2025, veterans can get buprenorphine treatment and follow-up care through telemedicine, making it easier to access help for opioid use disorder without leaving home. This change affects veterans using VA health services and aims to improve treatment access while the government reviews feedback and policies. No new costs are mentioned, but the delay gives agencies time to ensure the rules work well.
2025-02793, Expansion of Buprenorphine Treatment via Telemedicine Encounter and Continuity of Care via Telemedicine for Veterans Affairs Patients
The government is giving veterans easier access to buprenorphine treatment through telemedicine, letting them get care remotely. This change affects veterans using VA health services and aims to make treatment smoother and more convenient. The new rules were supposed to start February 18, 2025, but now they’ll kick in on March 21, 2025, while the government gathers public feedback.
2026-20749, Vladimir Romaniv, P.A.; Decision and Order
The DEA has officially suspended and is moving to revoke Vladimir Romaniv, P.A.'s registration because he gave multiple prescriptions without properly checking on a patient who was in jail. This affects Romaniv’s ability to prescribe controlled substances and signals serious legal trouble starting from late 2025. If you’re connected to his practice or rely on his prescriptions, expect changes and tighter controls soon.
2026-20750, L Krenk DBA Maui Clinic Pharmacy; Decision and Order
The DEA has officially revoked L Krenk DBA Maui Clinic Pharmacy’s registration because they broke important rules about where and how they handled controlled substances. This affects the pharmacy in Kahului, Hawaii, which can no longer legally dispense these drugs. The decision is final, and the pharmacy missed its chance to defend itself, so the revocation takes effect immediately, impacting their business and customers.
Previous / Next Documents
Previous: 2025-05064, National Institute on Drug Abuse; Notice of Closed Meetings
The National Institute on Drug Abuse is holding a closed virtual meeting on May 2, 2025, to review grant applications. This affects researchers seeking funding for drug abuse studies, ensuring their private info and ideas stay safe. No public access means the process stays fair and confidential, helping good science get the support it needs.
Next: 2025-05066, National Institute of Diabetes and Digestive and Kidney Diseases; Notice of Closed Meeting
The National Institute of Diabetes and Digestive and Kidney Diseases is holding a closed virtual meeting from June 24-26, 2025, to review grant applications related to kidney, urologic, and blood diseases. This meeting affects researchers seeking funding and keeps sensitive information private. No money changes are announced, but the review helps decide who gets research support.